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	 Is	immediate-release		
topiramate	an	effective		
treatment	for	adult	obesity?	
	 Yes.	 Topiramate	 (at	 daily	 doses	
	 of	64-400	mg)	produces	an	average	
5.34	kg	of	additional	weight	loss	compared	
with	placebo	(95%	confidence	interval	[CI],	
-6.12	to	-4.56)	in	overweight	to	obese	adults	
for	 periods	 of	 16	 to	 60	 weeks	 (strength	 of	
recommendation	 [SOR]:	A,	 meta-analyses	
of	randomized	controlled	trials	[RCTs]).	
Topiramate	 increases	 the	 chances	 of	
losing	5%	or	more	of	baseline	body	weight	
(BBW)	 with	 a	 number	 needed	 to	 treat	
(NNT)	of	3	(95%	CI,	2-3)	and	10%	or	more	
of	 BBW	with	 an	 NNT	 of	 4	 (95%	 CI,	 3-4).	
However,	 approximately	 17%	 of	 patients	
discontinue	 the	 drug	 because	 of	 adverse	
effects,	 including	 paresthesia,	 hypoesthe-
sia,	taste	perversion,	and	psychomotor	im-
pairment	(SOR:	A,	meta-analyses	of	RCTs).
Evidence summary
A	meta-analysis	of	10	well-done	RCTs	with	a	
total	 of	 3320	 patients	 found	 that	 topiramate	
produced	 more	 weight	 loss	 than	 placebo.1	
Studies	 included	men	 and	women	 ages	 18	 to	
75	 years,	 with	 a	 body	 mass	 index	 (BMI)	 of	
27	 to	 50.	 Several	 studies	 included	 patients	
with	 hypertension,	 dyslipidemia,	 and	 diabe-
tes	mellitus;	one	study	included	patients	with	
binge	 eating	 disorder.	 Investigators	 recruited	
subjects	from	sites	in	Europe,	North	America,	
Australia,	and	South	Africa.	The	studies	lasted	
16	to	60	weeks	and	used	variable	doses	of	topi-
ramate	(64-400	mg	daily).	Most	 incorporated	
a	structured	lifestyle	intervention	program	for	
both	the	treatment	and	control	groups.
Patients	 taking	 topiramate	 lost	 5.34	 kg	
(95%	 CI,	 -6.12	 to	 -4.56)	more	 than	 subjects	
taking	 placebo.	 All	 studies	 showed	 signifi-
cantly	 greater	weight	 loss	 in	 the	 topiramate	
groups,	 regardless	 of	 dose	 and	duration,	 al-
though	there	was	some	heterogeneity	among	
the	results.	The	NNTs	to	achieve	weight	 loss	
of	 5%	 or	more	 of	 BBW	 and	 10%	 or	more	 of	
BBW	were	3	(95%	CI,	2-3)	and	4	(95%	CI,	3-4),	
respectively.
no major adverse events,  
but some unpleasant effects
A	safety	analysis	on	6620	subjects	 found	no	
major	adverse	events.1	Subjects	in	the	topira-
mate	group	were	more	likely	to	withdraw	be-
cause	of	adverse	effects	(odds	ratio=1.97;	95%	
CI,	 1.64-2.29;	 number	 needed	 to	 harm=14;	
95%	CI,	 11-18).	The	most	 common	 adverse	
effects	were	paresthesia,	hypoesthesia,	taste	
perversion,	 and	 psychomotor	 impairment,	
and	these	effects	were	most	likely	to	lead	to	
discontinuation	at	daily	doses	>96	mg.	
two formulas are effective  
in patients with diabetes 
Investigators	 stopped	 6	 studies	 early	 be-
cause	 the	 sponsor	wanted	 to	pursue	devel-
opment	of	a	controlled-release	 formulation	
of	 topiramate.	 The	 meta-analysis	 includes	
a	 single	 study	 of	 controlled-release	 topi-
ramate,	 175	 mg	 daily	 in	 patients	 with	 dia-
betes,	 that	 showed	 equivalent	 efficacy	 and	
similar	 tolerability	 to	 immediate-release	
topiramate.2
Three	other	RCTs	included	in	the	meta-
analysis	 specifically	 examined	 obese	 pa-
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tients	 with	 type	 2	 diabetes,	 a	 population	
deemed	more	resistant	to	typical	weight	loss	
regimens,	 treated	 with	 immediate-release	
topiramate	in	dosages	of	96	mg	and	192	mg	
daily.3-5	 These	 patients	 also	 experienced	
greater	weight	loss	than	patients	taking	pla-
cebo,	 comparable	 to	 what	 was	 seen	 in	 the	
overall	meta-analysis.
FDA approval and cost of therapy
Topiramate	monotherapy	 isn’t	 approved	 by	
the	US	Food	and	Drug	Administration	(FDA)	
for	 obesity	 treatment.	 In	 2012,	 the	 FDA	 ap-
proved	 phentermine/topiramate	 extended-
release	 (Qsymia)	 for	 long-term	 treatment	of	
obesity;	 the	monthly	cost	 for	a	maintenance	
dose	of	7.5	mg/46	mg	daily	is	approximately	
$185.6	Topiramate	immediate-release	tablets	
cost	 approximately	 $25	per	month	 for	 twice	
daily	doses	of	50	to	100	mg.7
Recommendations
The	 US	 Preventive	 Services	 Task	 Force	 rec-
ommends	screening	all	adults	 for	obesity	by	
measuring	BMI	and	referring	patients	with	a	
BMI	 ≥30	 for	 high-intensity,	 comprehensive	
behavioral	interventions.	It	makes	no	recom-
mendation	for	pharmacologic	management.8
The	 Institute	 for	 Clinical	 Systems	 Im-
provement	concludes	 that	pharmacotherapy	
should	be	used	only	as	part	of	a	comprehen-
sive	obesity	treatment	plan.	Pharmacotherapy	
should	be	considered	if	obese	patients	are	un-
able	to	lose	1	pound	per	week	with	diet,	physi-
cal	activity,	and	behavior	modification.9										JFP
	 1.			Kramer	CK,	Leitão	CB,	Pinto	LC,	et	al.	Efficacy	and	safety	of	
topiramate	 on	 weight	 loss:	 a	 meta-analysis	 of	 randomized	
controlled	trials.	Obes Rev.	2011;12:e338-e347.	
	 2.			Rosenstock	 J,	Hollander	P,	Gadde	KM,	et	 al;	OBD-202	Study	
Group.	A	randomized,	double-blind,	placebo-controlled,	mul-
ticenter	study	 to	assess	 the	efficacy	and	safety	of	 topiramate	
controlled	 release	 in	 the	 treatment	 of	 obese	 type	 2	 diabetic	
patients.	Diabetes Care.	2007;30:1480-1486.	
	 3.			Stenlöf	 K,	 Rössner	 S,	 Vercruysse	 F,	 et	 al.	 Topiramate	 in	 the	
treatment	of	obese	subjects	with	drug-naive	 type	2	diabetes.	
Diabetes Obes Metab.	2007;9:360-368.	
	 4.	 	Toplak	 H,	 Hamann	 A,	 Moore	 R,	 et	 al.	 Efficacy	 and	 safety	
of	 topiramate	 in	 combination	 with	 metformin	 in	 the	 treat-
ment	 of	 obese	 subjects	with	 type	 2	 diabetes:	 a	 randomized,	
double-blind,	 placebo-controlled	 study.	 Int J Obes (Lond).	
2007;31:138-146.	
	 5.			Eliasson	 B,	 Gudbjörnsdottir	 S,	 Cederholm	 J,	 et	 al.	 Weight	
loss	 and	 metabolic	 effects	 of	 topiramate	 in	 overweight	
and	 obese	 type	 2	 diabetic	 patients:	 randomized	 double-
blind	 placebo-controlled	 trial.	 Int J Obes (Lond).	 2007;31:
1140-1147.	
	 6.			Drugs.com.	Qsymia.	Drugs.com	Web	site.	Available	at:	www.
drugs.com/pro/qsymia.html.	Accessed	September	26,	2014.	
	 7.			Drugs.com.	Topirimate	prices,	coupons	and	patient	assistance	
programs.	Drugs.com	Web	site.	Available	at:	www.drugs.com/
price-guide/topiramate.	Accessed	September	26,	2014.	
	 8.			US	Preventive	Services	Task	Force.	Obesity	in	Adults:	Screening	
and	management.	US	Preventive	Services	Task	Force	Web	site.	
Available	at:	www.uspreventiveservicestaskforce.org/uspstf11/
obeseadult/obesers.htm.	Accessed	September	30,	2014.
	 9.			Fitch	A,	Everling	L,	Fox	C,	et	al.	Prevention	and	management	of	
obesity	 for	 adults.	 Institute	 for	 Clinical	 Systems	 Improvement	
Web	 site.	 Available	 at:	 www.icsi.org/_asset/s935hy/Obesity-
Adults.pdf.	Accessed	September	30,	2014.
MEDJOBNETWORK  com
Physician    NP/PA Career Center
The first mobile job board  
for Physicians, NPs, and PAs
Mobile Job Searches—access MedJobNetwork.com 
on the go from your smartphone or tablet
Advanced Search Capabilities—search for jobs 
by specialty, job title, geographic location,  
employers, and more
Scan this QR code  
to access the mobile version  
of MedJobNetwork.com
